Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Elahe Taki, Faezeh Soleimani, Arezoo Asadi, Hossein Ghahramanpour, Ali Namvar & Mohsen Heidary. (2022) Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. Expert Review of Anti-infective Therapy 20:8, pages 1135-1147.
Read now
Read now
Yali Wang, Erik De Clercq & Guangdi Li. (2019) Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opinion on Drug Metabolism & Toxicology 15:10, pages 813-829.
Read now
Read now
Laura Benítez-Gutiérrez, Vicente Soriano, Silvia Requena, Ana Arias, Pablo Barreiro & Carmen de Mendoza. (2018) Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert Review of Clinical Pharmacology 11:5, pages 507-517.
Read now
Read now
Rana Zainuddin, Zahid Zaheer, Jaiprakash N. Sangshetti & Mufassir Momin. (2017) Enhancement of oral bioavailability of anti-HIV drug rilpivirine HCl through nanosponge formulation. Drug Development and Industrial Pharmacy 43:12, pages 2076-2084.
Read now
Read now
Onyema Ogbuagu. (2016) Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert Review of Anti-infective Therapy 14:12, pages 1113-1126.
Read now
Read now
Yu-Jung Cha, Kyoung Soo Lim, Min-Kyu Park, Stephen Schneider, Brian Bray, Myung-Chol Kang, Jae-Yong Chung, Seo Hyun Yoon, Joo-Youn Cho & Kyung-Sang Yu. (2014) Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects. Drug Design, Development and Therapy 8, pages 1613-1619.
Read now
Read now
Nathan Ford & Alexandra Calmy. (2012) Expert reviews: who are they for?. Expert Opinion on Pharmacotherapy 13:8, pages 1083-1085.
Read now
Read now
Nathan Ford, Janice Lee, Isabelle Andrieux-Meyer & Alexandra Calmy. (2011) Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV/AIDS - Research and Palliative Care 3, pages 35-44.
Read now
Read now
Raktim Kumar Ghosh, Samhati Mondal Ghosh & Shalini Chawla. (2011) Recent advances in antiretroviral drugs. Expert Opinion on Pharmacotherapy 12:1, pages 31-46.
Read now
Read now
Articles from other publishers (38)
Lu Sun, Peng Nie, Li Luan, Piet Herdewijn & Ya-Tao Wang. (2023) Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update. European Journal of Medicinal Chemistry 261, pages 115847.
Crossref
Crossref
Ya-Li Sang, Christophe Pannecouque, Erik De Clercq, Shuai Wang & Fen-Er Chen. (2023) Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability. Acta Pharmaceutica Sinica B 13:7, pages 3054-3066.
Crossref
Crossref
Ethel D. Weld, Teresa L. Parsons, Ryann Gollings, Marybeth McCauley, Beatriz Grinsztejn, Raphael J. Landovitz & Mark A. Marzinke. (2023) Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots. Journal of Pharmaceutical and Biomedical Analysis 228, pages 115307.
Crossref
Crossref
Xin Jin, Li-Min Zhao, Shuai Wang, Wen-Juan Huang, Yin-Xiang Zhang, Christophe Pannecouque, Erik De Clercq & Fen-Er Chen. (2022)
Structure-Based Discovery of Novel NH
2
-Biphenyl-Diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH
2
-Naphthyl-Diarylpyrimidine to NH
2
-Biphenyl-Diarylpyrimidine
. Journal of Medicinal Chemistry 65:12, pages 8478-8492.
Crossref
Crossref
Leena Zino, Jurjen S. Kingma, Catia Marzolini, Olivier Richel, David M. Burger & Angela Colbers. (2022) Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV. Clinical Pharmacokinetics 61:5, pages 619-635.
Crossref
Crossref
Li Ding, Chunlin Zhuang & Fener Chen. (2021) Druggability modification strategies of the diarylpyrimidine‐type non‐nucleoside reverse transcriptase inhibitors. Medicinal Research Reviews 41:3, pages 1255-1290.
Crossref
Crossref
Li Ding, Christophe Pannecouque, Erik De Clercq, Chunlin Zhuang & Fen-Er Chen. (2021)
Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
N
-Alkylation to Methyl Hopping on the Pyrimidine Ring
. Journal of Medicinal Chemistry 64:8, pages 5067-5081.
Crossref
Crossref
Herana Kamal SeneviratneJoseph TillotsonJulie M. LadeLinda-Gail BekkerSue LiSubash PathakJessica JustmanNyaradzo MgodiShobha SwaminathanNirupama SistaJennifer FarriorPaul RichardsonCraig W. HendrixNamandje N. Bumpus. (2021) Metabolism of Long-Acting Rilpivirine After Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076). AIDS Research and Human Retroviruses 37:3, pages 173-183.
Crossref
Crossref
Elizabeth D. Kim, Catherine D. Kim, Joseph Chaney & Sunyoung Kim. 2021. Encyclopedia of Biological Chemistry III. Encyclopedia of Biological Chemistry III
27
43
.
Beatriz Suay‐Garcia, Jose Ignacio Bueso‐Bordils, Antonio Falcó, María Teresa Pérez‐Gracia, Gerardo Antón‐Fos & Pedro Alemán‐López. (2020) Quantitative structure–activity relationship methods in the discovery and development of antibacterials. WIREs Computational Molecular Science 10:6.
Crossref
Crossref
Dario Cattaneo, Tiziana Formenti, Bronzino Isabella, Carlo Filice, Marta Fusi & Cristina Gervasoni. (2020) Effects of ursodeoxycholic acid on rilpivirine plasma trough concentrations: a case report. European Journal of Clinical Pharmacology 76:4, pages 605-606.
Crossref
Crossref
Anita Leporati, Suresh Gupta, Elijah Bolotin, Gerardo Castillo, Joshua Alfaro, Marina B. Gottikh & Alexei A. Bogdanov Jr. (2019) Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application. Pharmaceutical Research 36:5.
Crossref
Crossref
Saima Aftab, Sevinc Kurbanoglu, Goksu Ozcelikay, Nurgul K. Bakirhan, Afzal Shah & Sibel A. Ozkan. (2019) Carbon quantum dots co-catalyzed with multiwalled carbon nanotubes and silver nanoparticles modified nanosensor for the electrochemical assay of anti-HIV drug Rilpivirine. Sensors and Actuators B: Chemical 285, pages 571-583.
Crossref
Crossref
Ahizechukwu C. Eke, Nahida Chakhtoura, Angela Kashuba, Brookie M. Best, Craig Sykes, Jiajia Wang, Alice M. Stek, Elizabeth Smith, Samantha Calabrese, Edmund V. Capparelli & Mark Mirochnick. (2018) Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum. JAIDS Journal of Acquired Immune Deficiency Syndromes 78:3, pages 308-313.
Crossref
Crossref
Larry Yet. 2018. Privileged Structures in Drug Discovery. Privileged Structures in Drug Discovery
237
283
.
Josef Reznicek, Martina Ceckova, Zuzana Ptackova, Ondrej Martinec, Lenka Tupova, Lukas Cerveny & Frantisek Staud. (2017) MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption. Antimicrobial Agents and Chemotherapy 61:9.
Crossref
Crossref
Yaser Hosseini, Adriano Mollica & Sako Mirzaie. (2016) Structure-based virtual screening efforts against HIV-1 reverse transcriptase to introduce the new potent non-nucleoside reverse transcriptase inhibitor. Journal of Molecular Structure 1125, pages 592-600.
Crossref
Crossref
Ying-Yuan Lu, Xiao-Wei Wang, Xin Wang, Wen-Bing Dai, Qiang Zhang, Pu Li, Ya-Qing Lou, Chuang Lu, Jun-Yi Liu & Guo-Liang Zhang. (2016) Profile of disposition, tissue distribution and excretion of the novel anti-human immunodeficiency virus (HIV) agent W-1 in rats. Archives of Pharmacal Research 39:7, pages 970-977.
Crossref
Crossref
Raphael J. Landovitz, Ryan Kofron & Marybeth McCauley. (2016) The promise and pitfalls of long-acting injectable agents for HIV prevention. Current Opinion in HIV and AIDS 11:1, pages 122-128.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
687
736
.
Laura Dickinson, H. Manisha Yapa, Akil Jackson, Graeme Moyle, Laura Else, Alieu Amara, Saye Khoo, David Back, Zeenat Karolia, Chris Higgs & Marta Boffito. (2015) Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. Antimicrobial Agents and Chemotherapy 59:10, pages 6080-6086.
Crossref
Crossref
Roberto Rossotti, Luigi Fonte, Genny Meini, Franco Maggiolo, Maurizio Zazzi & Stefano Rusconi. (2014) Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: Analysis from a national drug-resistance database (ARCA). Journal of Medical Virology 86:9, pages 1459-1466.
Crossref
Crossref
A. Hill, S. Geißler, M. Meyring, S. Hecht, M. Weigandt & K. Mäder. (2013) In vitro–in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps. International Journal of Pharmaceutics 451:1-2, pages 57-66.
Crossref
Crossref
Hong X. Ding, Kevin K.-C. Liu, Subas M. Sakya, Andrew C. Flick & Christopher J. O’Donnell. (2013) Synthetic approaches to the 2011 new drugs. Bioorganic & Medicinal Chemistry 21:11, pages 2795-2825.
Crossref
Crossref
Nicholas A. Meanwell, Stanley V. D'Andrea, Christopher W. Cianci, Ira B. Dicker, Kap‐Sun Yeung, Makonen Belema & Mark Krystal. 2013. Drug Discovery. Drug Discovery
439
515
.
M. Sharma & L. D. Saravolatz. (2012) Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. Journal of Antimicrobial Chemotherapy 68:2, pages 250-256.
Crossref
Crossref
Sofia A. Pereira, Riccardo Wanke, M. Matilde Marques, Emília C. Monteiro & Alexandra M.M. Antunes. 2012. Advances in Molecular Toxicology Volume 6. Advances in Molecular Toxicology Volume 6
1
39
.
Joanne Bronson, Murali Dhar, William Ewing & Nils Lonberg. 2012. Annual Reports in Medicinal Chemistry Volume 47. Annual Reports in Medicinal Chemistry Volume 47
499
569
.
Matthew Grant, Rafik Samuel, Robert L. Bettiker & Byungse Suh. (2011) Antiretroviral therapy 2010 update: Current practices and controversies. Archives of Pharmacal Research 34:7.
Crossref
Crossref
Erik De Clercq. 2011. Antiviral Drug Strategies. Antiviral Drug Strategies
377
389
.
Michael PfallerJohn Mills. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition
2723
2728
.
Donald J. AbrahamErik De Clercq. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
139
168
.
Jerome Guillemont, Luc Geeraert, Jan Heeres & Paul J. Lewi. 2010. Analogue-Based Drug Discovery II. Analogue-Based Drug Discovery II
409
441
.
Gerben van ′t Klooster, Eva Hoeben, Herman Borghys, Adriana Looszova, Marie-Paule Bouche, Frans van Velsen & Lieven Baert. (2010) Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation. Antimicrobial Agents and Chemotherapy 54:5, pages 2042-2050.
Crossref
Crossref
Giovanni Maga, Marco Radi, Marie-Aline Gerard, Maurizio Botta & Eric Ennifar. (2010) HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate. Viruses 2:4, pages 880-899.
Crossref
Crossref
Nathan Ford & Alexandra Calmy. (2010) Improving first-line antiretroviral therapy in resource-limited settings. Current Opinion in HIV and AIDS 5:1, pages 38-47.
Crossref
Crossref
Marie-Pierre de Béthune. (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009). Antiviral Research 85:1, pages 75-90.
Crossref
Crossref
Joaquín Portilla. (2009) Seguridad y tolerabilidad de etravirina. Enfermedades Infecciosas y Microbiología Clínica 27, pages 21-26.
Crossref
Crossref